{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:03:45Z","timestamp":1784901825796,"version":"3.55.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic options for children under 12\u2005years with severe atopic dermatitis (AD) who fail dupilumab remain limited. We retrospectively evaluated dupilumab-refractory moderate-to-severe AD treated with off-label upadacitinib in nine children. At week 24, the\u00a0median Eczema Area and Severity Index (EASI) decreased from 21 to 2, with 78% achieving EASI-75. Pruritus improved rapidly (median numerical rating scale 7 to 1). Treatment was generally well tolerated, with no serious adverse events observed. These findings provide preliminary real-world evidence suggesting that Janus kinase 1 inhibition may represent a potential therapeutic option in selected paediatric patients with severe disease. Larger prospective studies are needed to confirm long-term safety and efficacy.<\/jats:p>","DOI":"10.1093\/ced\/llag143","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:48:14Z","timestamp":1774442894000},"page":"1482-1485","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib in children under 12\u2005years with dupilumab-refractory severe atopic dermatitis: a real-world case series"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0492-0969","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Vidal Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"L\u00f3pez Alc\u00e1zar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-0823","authenticated-orcid":false,"given":"Rafael","family":"Escudero Tornero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Antonio","family":"Vergara Barria","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Amat S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Maseda Pedrero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Feito Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"De Lucas Laguna","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026072409171543200_llag143-B1","first-page":"1136","article-title":"Atopic dermatitis","volume-title":"N Engl J Med","author":"St\u00e4nder","year":"2021"},{"key":"2026072409171543200_llag143-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026072409171543200_llag143-B3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ijd.17723","article-title":"Evidence-based recommendations for managing atopic dermatitis in pediatric patients: a systematic review and meta-analysis from the pediatric dermatology special interest group of IADVL","volume":"64","author":"Mahajan","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026072409171543200_llag143-B4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamadermatol.2024.3696","article-title":"Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks","volume":"160","author":"Paller","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026072409171543200_llag143-B5","doi-asserted-by":"crossref","first-page":"e70045","DOI":"10.1111\/pai.70045","article-title":"Comparative efficacy of biologics and small molecule drugs in treating pediatric atopic dermatitis in patients aged 2\u201318\u2005years: a 12\u201316 week network meta-analysis of randomized controlled trials","volume":"36","author":"Yong","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"key":"2026072409171543200_llag143-B6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clinthera.2024.07.003","article-title":"Pharmacokinetics, safety, tolerability, and exploratory efficacy of upadacitinib in children with severe atopic dermatitis","volume":"46","author":"Qian","year":"2024","journal-title":"Clin Ther"},{"key":"2026072409171543200_llag143-B7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/pde.15468","article-title":"Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: a systematic review in pediatric patients","volume":"41","author":"Kouwenhoven","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2026072409171543200_llag143-B8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026072409171543200_llag143-B9","doi-asserted-by":"crossref","first-page":"e15636","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026072409171543200_llag143-B10","doi-asserted-by":"crossref","first-page":"e0319400","DOI":"10.1371\/journal.pone.0319400","article-title":"Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: a systematic review and network meta-analysis","volume":"20","author":"Liao","year":"2025","journal-title":"PLOS ONE"},{"key":"2026072409171543200_llag143-B11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/biomedicines12081841","article-title":"Biologic and small \u00admolecule\u00a0therapy in atopic dermatitis","volume":"12","author":"Shergill","year":"2024","journal-title":"Biomedicines"},{"key":"2026072409171543200_llag143-B12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/bjd\/ljad281","article-title":"Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial","volume":"189","author":"Flohr","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag143\/67529577\/llag143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1482\/67529577\/llag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1482\/67529577\/llag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:23Z","timestamp":1784899043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1482\/8541483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag143","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,26]]}}}